# NCT04309981 (NCT04309981)

> Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04309981
- Phase: PHASE1, PHASE2
- Status: UNKNOWN
- Sponsor: Sara V. Latorre
- Conditions: Relapsed/Refractory Multiple Myeloma
- Interventions: Adult differentiated autologous T-cells with anti-BCMA specificity
- Enrollment: 73
- Primary outcome: Overall response rate (ORR)
- Primary outcome: Cytokine release syndrome rate

## HCP commentary on NCT04309981 so far

What clinicians have said in podcasts, YouTube videos and X posts we have indexed. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04309981